Market Closed -
BME
11:39:17 2024-04-23 am EDT
After market
03:59:58 pm
8.658
EUR
+5.25%
8.579
-0.91%
Sales 2024 *
7.09B
7.59B
Sales 2025 *
7.63B
8.16B
Capitalization
4.98B
5.33B
Net income 2024 *
489M
523M
Net income 2025 *
732M
783M
EV / Sales 2024 *
1.99
x
Net Debt
2024
*
9.12B
9.76B
Net Debt
2025
*
8.33B
8.92B
EV / Sales 2025 *
1.75
x P/E ratio 2024 *
10.5
x
P/E ratio 2025 *
7.39
x
Employees
23,744
Yield 2024 *
-
Yield 2025 *
2.91%
Free-Float
89.28%
Duration
1 day 1 week 1 month 3 months 6 months 1 year 5 years 10 years
Period
5 minutes 15 minutes 30 minutes 1 hour 1 day 1 week 1 month 1 year
Style
CandleStick End-of-day OHLC Mountain
Dynamic Chart
European Equities Traded in the US as American Depositary Receipts Jump in Tuesday Trading
11:06am
MT
Grifols to Launch EUR1 Billion Note Offering
06:06am
MT
Grifols, S.A. Approves Board and Committee Changes
Apr. 18
CI
Grifols Plans to Appoint Independent Directors Only to Audit, Compensation Committees
Apr. 15
MT
Grifols to Add Independent Directors in Audit, Compensation Committees to Improve Governance
Apr. 15
MT
Spanish drug maker Grifols will bring in independent directors, chairman tells newspaper
Apr. 14
RE
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
Apr. 11
MT
GRIFOLS : Factoring in a more moderate earnings recovery; long-term view intact
Apr. 11
European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading
Apr. 10
MT
Grifols to refinance debt due in 2025 via sales of notes, Shanghai RAAS stake
Apr. 10
RE
Grifols Expects H1 Completion of Shanghai RAAS Stake Sale to Haier
Apr. 10
MT
Grifols Plans to Issue Senior Secured Notes
Apr. 10
MT
Global markets live: ASML, Walt Disney, McDonald's, Goldman Sachs, Apple...
Apr. 05
Spanish Drugmaker Grifols Issues Clarification to Watchdog on Previous EBITDA Calculations
Apr. 05
MT
Spain's Grifols gives new details on past EBITDA, leverage ratios to supervisor
Apr. 04
RE
More news
IN DIRETTA DAI MERCATI: Netweek, Ence Energia, Enel, OVS, Sogefi, Telecom Italia, ASML, Novartis, Airbus, Apple, Nvidia, Boeing...
04:29am
Grifols S A : anuncia la colocación de una emisión privada de 1.000M€ de bonos senior garantizados con vencimiento en 2030 23 abril 2024
03:32am
EN DIRECTO DESDE LOS MERCADOS: Enagas, Ence Energia, Acerinox, Naturgy, Endesa, Telefónica, Novartis, Apple, Nvidia, Boeing...
02:00am
EN DIRECTO DESDE LOS MERCADOS: Ferrovial, Repsol, Audax Renovables, Meliá Hotels, Vodafone, Brookfield, Amazon ...
Apr. 12
EN DIRECTO DESDE LOS MERCADOS: Vidrala, Acs, Aena, Repsol, Grifols, Sabadell, Indra, Lufthansa, UBS, Microsoft, Meta, Tesla...
Apr. 11
More news 1 day +4.90%
1 week -0.97%
Current month +3.29%
1 month +5.54%
3 months -4.20%
6 months -16.23%
Current year -44.28%
More quotes
Managers
Title Age Since
Chief Executive Officer
55
Feb. 05
Director of Finance/CFO
67
06-12-31
Chairman
65
06-04-04
Members of the board
Title Age Since
Chairman
65
06-04-04
Director/Board Member
68
00-04-12
Director/Board Member
61
01-07-26
More insiders
Date
Price
Change
Volume
24-04-23
8.658
+5.25%
3 251 068
24-04-22
8.226
-1.44%
2,744,119
24-04-19
8.346
-3.16%
3,288,156
24-04-18
8.618
-2.45%
1,907,396
24-04-17
8.834
+1.59%
2,493,069
Delayed Quote
BME, April 23, 2024 at 11:29 am EDT
More quotes
Grifols, S.A. specializes in the research, development, manufacturing and marketing of therapeutic products and medical devices for use in hospitals and medical analysis laboratories. Net sales break down by family of products and services as follows:
- products derived from plasma (84.3%): products for use by the pharmaceutical and biotechnology industries;
- diagnostic machines and reagents (10.2%): in vitro hemophilic diagnostic equipment, coagulation analyzers, infectious serology reagents, etc. for use primarily by blood banks and transfusion centers;
- hospital products (2.4%): non-biological surgical products, radiology and nutritional products, etc. for use by hospital pharmacies;
- other (3.1%): primarily intermediate biological products and subcontracted manufacturing services.
Net sales are distributed geographically as follows: Spain (5.5%), European Union (13.6%), the United States and Canada (59.1%) and other (21.8%).
More about the company
Last Close Price
8.226
EUR
Average target price
18.03
EUR
Spread / Average Target
+119.21%
Consensus
1st Jan change
Capi.
-44.28% 5.31B -2.68% 85.68B +4.08% 41.4B -24.67% 28.22B +54.31% 24.64B -5.00% 16.98B -42.09% 13.29B -17.22% 11.66B -12.10% 11.65B +0.37% 8.18B
Biopharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1